CCL20 and cancer: To further assess the therapeutic advantage of our NPs, we compared intratumoral treatment of free dox, the free combination therapy (dox+pIC+R848+MIP3α) and the NP-delivered combination therapy in two murine models of cancer: MC-38 and TC-1, using immunocompetent C57BL/6 mice.